Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00629187 · ClinicalTrials.gov registry record · Phase 1
Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy
A Phase 1 study, sponsored by Tufts Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00629187 is a Phase 1 study that was terminated before completion, run by Tufts Medical Center. The registered enrollment target is 2 participants.
The verdict
NCT00629187, a Phase 1 study, was terminated before completion, sponsored by Tufts Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The goal of this study is to find the maximum dose of a drug, temozolomide, that can safely be given to subjects with brain tumors. Past studies showed that the maximum dose of temozolomide was limited by low blood counts. The investigators will use blood stem cells collected from bone marrow to help subjects recover their blood counts, a procedure called autologous stem cell transplant or stem cell rescue. This way, the investigators expect to be able to safely deliver very high doses of temozolomide. This study is only available at Tufts Medical Center.
Interventions
- DRUG Temozolomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2004-04 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00629187
The ClinicalTrials.gov registry entry for NCT00629187 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Temozolomide is the first listed.
NCT00629187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00629187 about?
NCT00629187 is a clinical study titled "Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy". The goal of this study is to find the maximum dose of a drug, temozolomide, that can safely be given to subjects with brain tumors. Past studies showed that the maximum dose of temozolomide was limited by low blood counts. The investigators will use blood stem cells collected from bone marrow to hel...
What is the current status of trial NCT00629187?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2004-04. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00629187?
The interventions under investigation include: Temozolomide (DRUG).
Who is sponsoring clinical trial NCT00629187?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.